Please assess the completion status of the following clinical trial:

Trial Title: CoQ10 and D-ribose in Patients With Diastolic Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with HFpEF within a 6-month period~* New York Heart Association (NYHA) Classification II-III HF~* Have left ventricular ejection fraction (EF) ≥ 50% documented by an echocardiogram~* Have a telephone or reliable phone contact~* Have their own means of transportation to the study site~Exclusion Criteria:~* Acute coronary syndrome in the past 12 weeks~* Significant valvular heart disease~* Severe cardiac fibrosis (galectin-3 level \> 26 ng/ml)~* Constrictive pericardium~* Pulmonary fibrosis~* Congenital heart disease~* Hypertrophic or infiltrative cardiomyopathy~* Heart transplant~* Left ventricular assist device~* Heart failure (HF) associated hospital admission or emergency room visit within past 30 days~* Recent percutaneous coronary intervention~* Significant renal and/or hepatic dysfunction~* Severe cognitive impairment~* Consumption of any CoQ10 (ubiquinol) or D-ribose supplements

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Placebo Only (Type: PLACEBO_COMPARATOR): Participants in this group will receive placebo pills and placebo powder.
- CoQ10 Only (Type: ACTIVE_COMPARATOR): Participants in this group will receive CoQ10 pills and placebo powder
- D-ribose Only (Type: ACTIVE_COMPARATOR): Participants in this group will receive placebo pills and D-ribose oral powder.
- CoQ10 + D-ribose (Type: EXPERIMENTAL): Participants in this group will receive CoQ10 pills and D-ribose oral powder.

Based on this trial design, predict the completion outcome and termination type (if applicable).